Breast cancer is one of the most prevalent cancers affecting women worldwide. Early detection and treatment are crucial in significantly reducing mortality rates Microcalcifications (MCs) are of particular importance among the various breast lesions. These tiny calcium deposits within breast tissue are present in approximately 30% of malignant tumors and can serve as critical indirect indicators of early-stage breast cancer. Three or more MCs within an area of 1 cm² are considered a Microcalcification Cluster (MCC) and assigned a BI-RADS category 4, indicating a suspicion of malignancy. Mammography is the most used technique for breast cancer detection. Approximately one in two mammograms showing MCCs is confirmed as cancerous through biopsy. MCCs are challenging to detect, even for experienced radiologists, underscoring the need for computer-aided detection tools such as Convolutional Neural Networks (CNNs). CNNs require large amounts of domain-specific data with consistent resolutions for effective training. However, most publicly available mammogram datasets either lack resolution information or are compiled from heterogeneous sources. Additionally, MCCs are often either unlabeled or sparsely represented in these datasets, limiting their utility for training CNNs. In this dataset, we present the MEXBreast, an annotated MCCs Mexican digital mammogram database, containing images from resolutions of 50, 70, and 100 microns. MEXBreast aims to support the training, validation, and testing of deep learning CNNs.

<i>Radiology: Cardiothoracic Imaging</i> publishes research, technical developments, and reviews related to cardiac, vascular, and thoracic imaging. The current review article, led by the <i>Radiology: Cardiothoracic Imaging</i> trainee editorial board, highlights the most impactful articles published in the journal between November 2023 and October 2024. The review encompasses various aspects of cardiac, vascular, and thoracic imaging related to coronary artery disease, cardiac MRI, valvular imaging, congenital and inherited heart diseases, thoracic imaging, lung cancer, artificial intelligence, and health services research. Key highlights include the role of CT fractional flow reserve analysis to guide patient management, the role of MRI elastography in identifying age-related myocardial stiffness associated with increased risk of heart failure, review of MRI in patients with cardiovascular implantable electronic devices and fractured or abandoned leads, imaging of mitral annular disjunction, specificity of the Lung Imaging Reporting and Data System version 2022 for detecting malignant airway nodules, and a radiomics-based reinforcement learning model to analyze serial low-dose CT scans in lung cancer screening. Ongoing research and future directions include artificial intelligence tools for applications such as plaque quantification using coronary CT angiography and growing understanding of the interconnectedness of environmental sustainability and cardiovascular imaging. <b>Keywords:</b> CT, MRI, CT-Coronary Angiography, Cardiac, Pulmonary, Coronary Arteries, Heart, Lung, Mediastinum, Mitral Valve, Aortic Valve, Artificial Intelligence © RSNA, 2025.

In this narrative review, we address the ongoing challenges of lung cancer (LC) screening using chest low-dose computerized tomography (LDCT) and explore the contributions of artificial intelligence (AI), in overcoming them. We focus on evaluating the initial (baseline) LDCT examination, which provides a wealth of information relevant to the screening participant's health. This includes the detection of large-size prevalent LC and small-size malignant nodules that are typically diagnosed as LCs upon growth in subsequent annual LDCT scans. Additionally, the baseline LDCT examination provides valuable information about smoking-related comorbidities, including cardiovascular disease, chronic obstructive pulmonary disease, and interstitial lung disease (ILD), by identifying relevant markers. Notably, these comorbidities, despite the slow progression of their markers, collectively exceed LC as ultimate causes of death at follow-up in LC screening participants. Computer-assisted diagnosis tools currently improve the reproducibility of radiologic readings and reduce the false negative rate of LDCT. Deep learning (DL) tools that analyze the radiomic features of lung nodules are being developed to distinguish between benign and malignant nodules. Furthermore, AI tools can predict the risk of LC in the years following a baseline LDCT. AI tools that analyze baseline LDCT examinations can also compute the risk of cardiovascular disease or death, paving the way for personalized screening interventions. Additionally, DL tools are available for assessing osteoporosis and ILD, which helps refine the individual's current and future health profile. The primary obstacles to AI integration into the LDCT screening pathway are the generalizability of performance and the explainability.

PurposeWe aimed to investigate the external validation and performance of an FDA-approved deep learning model in labeling intracranial hemorrhage (ICH) cases on a real-world heterogeneous clinical dataset. Furthermore, we delved deeper into evaluating how patients' risk factors influenced the model's performance and gathered feedback on satisfaction from radiologists of varying ranks.MethodsThis prospective IRB approved study included 5600 non-contrast CT scans of the head in various clinical settings, that is, emergency, inpatient, and outpatient units. The patients' risk factors were collected and tested for impacting the performance of DL model utilizing univariate and multivariate regression analyses. The performance of DL model was contrasted to the radiologists' interpretation to determine the presence or absence of ICH with subsequent classification into subcategories of ICH. Key metrics, including accuracy, sensitivity, specificity, positive predictive value, and negative predictive value, were calculated. Receiver operating characteristics curve, along with the area under the curve, were determined. Additionally, a questionnaire was conducted with radiologists of varying ranks to assess their experience with the model.ResultsThe model exhibited outstanding performance, achieving a high sensitivity of 89% and specificity of 96%. Additional performance metrics, including positive predictive value (82%), negative predictive value (97%), and overall accuracy (94%), underscore its robust capabilities. The area under the ROC curve further demonstrated the model's efficacy, reaching 0.954. Multivariate logistic regression revealed statistical significance for age, sex, history of trauma, operative intervention, HTN, and smoking.ConclusionOur study highlights the satisfactory performance of the DL model on a diverse real-world dataset, garnering positive feedback from radiology trainees.

The deployment of AI in medical imaging, particularly in areas such as fracture detection, represents a transformative advancement in orthopaedic care. AI-driven systems, leveraging deep-learning algorithms, promise to enhance diagnostic accuracy, reduce variability, and streamline workflows by analyzing radiograph images swiftly and accurately. Despite these potential benefits, the integration of AI into clinical settings faces substantial barriers, including slow adoption across health systems, technical challenges, and a major lag between technology development and clinical implementation. This commentary explores the role of AI in healthcare, highlighting its potential to enhance patient outcomes through more accurate and timely diagnoses. It addresses the necessity of bridging the gap between AI innovation and practical application. It also emphasizes the importance of implementation science in effectively integrating AI technologies into healthcare systems, using frameworks such as the Consolidated Framework for Implementation Research and the Knowledge-to-Action Cycle to guide this process. We call for a structured approach to address the challenges of deploying AI in clinical settings, ensuring that AI's benefits translate into improved healthcare delivery and patient care.

This study aims to assess the effectiveness of integrating Segment Anything Model (SAM) and its variant MedSAM into the automated mining, object detection, and segmentation (MODS) methodology for developing robust lung cancer detection and segmentation models without post hoc labeling of training images. In a retrospective analysis, 10,000 chest computed tomography scans from patients with lung cancer were mined. Line measurement annotations were converted to bounding boxes, excluding boxes < 1 cm or > 7 cm. The You Only Look Once object detection architecture was used for teacher-student learning to label unannotated lesions on the training images. Subsequently, a final tumor detection model was trained and employed with SAM and MedSAM for tumor segmentation. Model performance was assessed on a manually annotated test dataset, with additional evaluations conducted on an external lung cancer dataset before and after detection model fine-tuning. Bootstrap resampling was used to calculate 95% confidence intervals. Data mining yielded 10,789 line annotations, resulting in 5403 training boxes. The baseline detection model achieved an internal F1 score of 0.847, improving to 0.860 after self-labeling. Tumor segmentation using the final detection model attained internal Dice similarity coefficients (DSCs) of 0.842 (SAM) and 0.822 (MedSAM). After fine-tuning, external validation showed an F1 of 0.832 and DSCs of 0.802 (SAM) and 0.804 (MedSAM). Integrating foundational segmentation models into the MODS framework results in high-performing lung cancer detection and segmentation models using only mined clinical data. Both SAM and MedSAM hold promise as foundational segmentation models for radiology images.

Prostate-specific membrane antigen (PSMA) molecular imaging is widely used for disease assessment in prostate cancer (PC). Artificial intelligence (AI) platforms such as automated Prostate Cancer Molecular Imaging Standardized Evaluation (aPROMISE) identify and quantify locoregional and distant disease, thereby expediting lesion identification and standardizing reporting. Our aim was to evaluate the ability of the updated aPROMISE platform to assess treatment responses based on integration of the RECIP (Response Evaluation Criteria in PSMA positron emission tomography-computed tomography [PET/CT]) 1.0 classification. The study included 33 patients with castration-sensitive PC (CSPC) and 34 with castration-resistant PC (CRPC) who underwent PSMA-targeted molecular imaging before and ≥2 mo after completion of treatment. Tracer-avid lesions were identified using aPROMISE for pretreatment and post-treatment PET/CT scans. Detected lesions were manually approved by an experienced nuclear medicine physician, and total tumor volume (TTV) was calculated. Response was assessed according to RECIP 1.0 as CR (complete response), PR (partial response), PD (progressive disease), or SD (stable disease). KEY FINDINGS AND LIMITATIONS: aPROMISE identified 1576 lesions on baseline scans and 1631 lesions on follow-up imaging, 618 (35%) of which were new. Of the 67 patients, aPROMISE classified four as CR, 16 as PR, 34 as SD, and 13 as PD; five cases were misclassified. The agreement between aPROMISE and clinician validation was 89.6% (κ = 0.79). aPROMISE may serve as a novel assessment tool for treatment response that integrates PSMA PET/CT results and RECIP imaging criteria. The precision and accuracy of this automated process should be validated in prospective clinical studies. We used an artificial intelligence (AI) tool to analyze scans for prostate cancer before and after treatment to see if we could track how cancer spots respond to treatment. We found that the AI approach was successful in tracking individual tumor changes, showing which tumors disappeared, and identifying new tumors in response to prostate cancer treatment.

This study aims to evaluate a deep learning pipeline for detecting clinically significant prostate cancer (csPCa), defined as Gleason Grade Group (GGG) ≥ 2, using biparametric MRI (bpMRI) and compare its performance with radiological reading. The training dataset included 4381 bpMRI cases (3800 positive and 581 negative) across three continents, with 80% annotated using PI-RADS and 20% with Gleason Scores. The testing set comprised 328 cases from the PROSTATEx dataset, including 34% positive (GGG ≥ 2) and 66% negative cases. A 3D nnU-Net was trained on bpMRI for lesion detection, evaluated using histopathology-based annotations, and assessed with patient- and lesion-level metrics, along with lesion volume, and GGG. The algorithm was compared to non-expert radiologists using multi-parametric MRI (mpMRI). The model achieved an AUC of 0.83 (95% CI: 0.80, 0.87). Lesion-level sensitivity was 0.85 (95% CI: 0.82, 0.94) at 0.5 False Positives per volume (FP/volume) and 0.88 (95% CI: 0.79, 0.92) at 1 FP/volume. Average Precision was 0.55 (95% CI: 0.46, 0.64). The model showed over 0.90 sensitivity for lesions larger than 650 mm³ and exceeded 0.85 across GGGs. It had higher true positive rates (TPRs) than radiologists equivalent FP rates, achieving TPRs of 0.93 and 0.79 compared to radiologists' 0.87 and 0.68 for PI-RADS ≥ 3 and PI-RADS ≥ 4 lesions (p ≤ 0.05). The DL model showed strong performance in detecting csPCa on an independent test cohort, surpassing radiological interpretation and demonstrating AI's potential to improve diagnostic accuracy for non-expert radiologists. However, detecting small lesions remains challenging. Question Current prostate cancer detection methods often do not involve non-expert radiologists, highlighting the need for more accurate deep learning approaches using biparametric MRI. Findings Our model outperforms radiologists significantly, showing consistent performance across Gleason Grade Groups and for medium to large lesions. Clinical relevance This AI model improves prostate detection accuracy in prostate imaging, serves as a benchmark with reference performance on a public dataset, and offers public PI-RADS annotations, enhancing transparency and facilitating further research and development.

Breast cancer continues to be a major health concern, and early detection is vital for enhancing survival rates. Magnetic resonance imaging (MRI) is a key tool due to its substantial sensitivity for invasive breast cancers. Computer-aided detection (CADe) systems enhance the effectiveness of MRI by identifying potential lesions, aiding radiologists in focusing on areas of interest, extracting quantitative features, and integrating with computer-aided diagnosis (CADx) pipelines. This review aims to provide a comprehensive overview of the current state of CADe systems in breast MRI, focusing on the technical details of pipelines and segmentation models including classical intensity-based methods, supervised and unsupervised machine learning (ML) approaches, and the latest deep learning (DL) architectures. It highlights recent advancements from traditional algorithms to sophisticated DL models such as U-Nets, emphasizing CADe implementation of multi-parametric MRI acquisitions. Despite these advancements, CADe systems face challenges like variable false-positive and negative rates, complexity in interpreting extensive imaging data, variability in system performance, and lack of large-scale studies and multicentric models, limiting the generalizability and suitability for clinical implementation. Technical issues, including image artefacts and the need for reproducible and explainable detection algorithms, remain significant hurdles. Future directions emphasize developing more robust and generalizable algorithms, integrating explainable AI to improve transparency and trust among clinicians, developing multi-purpose AI systems, and incorporating large language models to enhance diagnostic reporting and patient management. Additionally, efforts to standardize and streamline MRI protocols aim to increase accessibility and reduce costs, optimizing the use of CADe systems in clinical practice. LEVEL OF EVIDENCE: NA TECHNICAL EFFICACY: Stage 2.